Daybue (trofinetide) / Daybue STIX prior authorization
Prior authorization / step-edit form and criteria for Daybue (trofinetide) oral solution and Daybue STIX packets for treatment of classical/typical Rett syndrome for AvMed members; includes initial and reauthorization clinical requirements, dosing/quantity limits, and specialty pharmacy/vendor information.
No material clinical or coverage changes reported for this policy.
Coverage Summary
Prior authorization / step-edit form and clinical criteria for Daybue (trofinetide) oral solution and Daybue STIX packets for treatment of classical/typical Rett syndrome are required for AvMed members. Coverage stance: covered_with_criteria. Initial authorization duration: 12 months. Reauthorization duration: 12 months. The policy includes clinical requirements for diagnosis confirmation, prescriber specialty, exclusionary findings, required baseline assessments, dosing/quantity limits, and specialty pharmacy/vendor information.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.